{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:36:45Z","timestamp":1792697805045,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008220","name":"Canadian Foundation for AIDS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010633","name":"The Philadelphia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002784","name":"Canada Excellence Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.bcp.2021.114462","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T01:51:14Z","timestamp":1612921874000},"page":"114462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency"],"prefix":"10.1016","volume":"186","author":[{"given":"Cole","family":"Schonhofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Sciorillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Andrae-Marobela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Cochrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zabrina L.","family":"Brumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Brockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Mounzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-6482","authenticated-orcid":false,"given":"Kwasi","family":"Gyampoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis J.","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Tietjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2021.114462_b0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","article-title":"A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population","volume":"7","author":"Chawla","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.bcp.2021.114462_b0010","doi-asserted-by":"crossref","unstructured":"Zicari, S., Sessa, L., Cotugno, N., Ruggiero, A., Morrocchi, E., Concato, C., Rocca, S., Zangari, P., Manno, E.C., and Palma, P. (2019) Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 11, 200.","DOI":"10.3390\/v11030200"},{"key":"10.1016\/j.bcp.2021.114462_b0015","doi-asserted-by":"crossref","unstructured":"Besnard, E., Hakre, S., Kampmann, M., Lim, H.W., Hosmane, N.N., Martin, A., Bassik, M.C., Verschueren, E., Battivelli, E., Chan, J., Svensson, J.P., Gramatica, A., Conrad, R.J., Ott, M., Greene, W.C., Krogan, N.J., Siliciano, R.F., Weissman, J.S., and Verdin, E. (2016) The mTOR complex controls HIV latency. Cell Host Microbe. 14, 785-797.","DOI":"10.1016\/j.chom.2016.11.001"},{"key":"10.1016\/j.bcp.2021.114462_b0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2017.08.013","article-title":"Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription","volume":"146","author":"Hayashi","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2021.114462_b0025","doi-asserted-by":"crossref","first-page":"e01744","DOI":"10.1128\/AAC.01744-18","article-title":"Inhibitors of signaling pathways that block reversal of HIV-1 latency","volume":"63","author":"Vargas","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2021.114462_b0030","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2017.09.080","article-title":"In vivo suppression of HIV rebound by didehydro-cortistatin A, a \u201cblock-and-lock\u201d strategy for HIV-1 treatment","volume":"21","author":"Kessing","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2021.114462_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/fvl-2018-0205","article-title":"HIV cure strategies: a complex approach for a complicated viral reservoir?","volume":"14","author":"Marsden","year":"2019","journal-title":"Future Virol."},{"key":"10.1016\/j.bcp.2021.114462_b0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.it.2016.12.003","article-title":"HIV latency: Should we shock or lock?","volume":"38","author":"Darcis","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bcp.2021.114462_b0045","doi-asserted-by":"crossref","unstructured":"Delannoy, A., Poirier, M., Bell, B. (2019) Cat and mouse: HIV transcription in latency, immune evasion and cure\/remission strategies. Viruses. 11, 269.","DOI":"10.3390\/v11030269"},{"key":"10.1016\/j.bcp.2021.114462_b0050","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1101\/gad.11.20.2633","article-title":"P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro","volume":"11","author":"Mancebo","year":"1997","journal-title":"Genes Dev."},{"key":"10.1016\/j.bcp.2021.114462_b0055","doi-asserted-by":"crossref","unstructured":"Ping, Y.H. and Rana, T.M. (2001) DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. J. Biol. Chem. 276, 12951\u201312958.","DOI":"10.1074\/jbc.M006130200"},{"key":"10.1016\/j.bcp.2021.114462_b0060","doi-asserted-by":"crossref","unstructured":"Asamitsu, K., Fujinaga, K., and Okamoto, T. (2018) HIV Tat\/P-TEFb interaction: A potential target for novel anti-HIV therapies. Molecules. 23, 933.","DOI":"10.3390\/molecules23040933"},{"issue":"4","key":"10.1016\/j.bcp.2021.114462_b0065","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00465-15","article-title":"The tat inhibitor Didehydro-Cortistatin A prevents HIV-1 reactivation from latency","volume":"6","author":"Mousseau","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.bcp.2021.114462_b0070","doi-asserted-by":"crossref","unstructured":"Li, C., Mousseau, G., and Valente, S.T. (2019) Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat. Epigenetics Chromatin. 12, 23.","DOI":"10.1186\/s13072-019-0267-8"},{"key":"10.1016\/j.bcp.2021.114462_b0075","doi-asserted-by":"crossref","unstructured":"Kyei, G.B., Meng, S., Ramani, R., Niu, A., Lagisetti, C., Webb, T.R., and Ratner, L. (2018) Splicing factor 3B subunit 1 interacts with HIV tat and plays a role in viral transcription and reactivation from latency. mBio. 9, e01423-18.","DOI":"10.1128\/mBio.01423-18"},{"key":"10.1016\/j.bcp.2021.114462_b0080","doi-asserted-by":"crossref","unstructured":"Niu, Q., Liu, Z., Alamer, E., Fan, X., Chen, H., Endsley, J., Gelman, B.B., Tian, B., Kim, J.H., Michael, N.L., Robb, M.L., Ananworanich, J., Zhou, J., and Hu, H. (2019) Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. J. Clin. Invest. 129, 3361\u20133373.","DOI":"10.1172\/JCI120633"},{"issue":"1","key":"10.1016\/j.bcp.2021.114462_b0085","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/np50103a006","article-title":"Anti-AIDS agents, 10. Acacetin-7-O-\u03b2-D-galactopyranoside, an Anti-HIV principle from chrysanthemum morifolium and a structure-activity correlation with some related flavonoids","volume":"57","author":"Hu","year":"1994","journal-title":"J. Nat. Prod."},{"issue":"1","key":"10.1016\/j.bcp.2021.114462_b0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/aid.1996.12.39","article-title":"Inhibition of HIV activation in latently infected cells by flavonoid compounds","volume":"12","author":"Critchfield","year":"1996","journal-title":"AIDS Res. Human Retroviruses"},{"key":"10.1016\/j.bcp.2021.114462_b0095","doi-asserted-by":"crossref","unstructured":"Mehla, R., Bivalkar-Mehla, S., and Chauhan, A. (2011) A flavonoid, luteolin, cripples HIV-1 by abrogation of Tat function. PLoS One. 6, e27915.","DOI":"10.1371\/journal.pone.0027915"},{"issue":"7","key":"10.1016\/j.bcp.2021.114462_b0100","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.66","article-title":"Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1","volume":"2","author":"Polier","year":"2011","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bcp.2021.114462_b0105","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/2211-5463.12398","article-title":"The anti\u2010human cytomegalovirus drug tricin inhibits cyclin\u2010dependent kinase 9","volume":"8","author":"Sadanari","year":"2018","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bcp.2021.114462_b0110","doi-asserted-by":"crossref","first-page":"28345","DOI":"10.1074\/jbc.C000446200","article-title":"Flavopiridol inhibits P-TEFb and blocks HIV-1 replication","volume":"275","author":"Chao","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2021.114462_b0115","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/mc.20866","article-title":"Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study","volume":"51","author":"Pandey","year":"2012","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.bcp.2021.114462_b0120","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-180","article-title":"Plant HDAC inhibitor chrysin arrest cell growth and induce p21 WAF1 by altering chromatin of STAT response element in A375 cells","volume":"12","author":"Pal-Bhadra","year":"2012","journal-title":"BMC Cancer"},{"issue":"1-3","key":"10.1016\/j.bcp.2021.114462_b0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejphar.2010.10.063","article-title":"Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells","volume":"651","author":"Attoub","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114462_b0130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tim.2013.02.005","article-title":"Reactivation of latent HIV by histone deacetylase inhibitors","volume":"21","author":"Shirakawa","year":"2013","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bcp.2021.114462_b0135","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jviromet.2005.08.003","article-title":"Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry","volume":"131","author":"Brockman","year":"2006","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.bcp.2021.114462_b0140","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/emboj\/cdg188","article-title":"HIV reproducibly establishes a latent infection after acute infection of T cells in vitro","volume":"22","author":"Jordan","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2021.114462_b0145","doi-asserted-by":"crossref","unstructured":"Butera, S.T., Perez, V.L., Wu, B.Y., Nabel, G.J., and Folks, T.M. (1991) Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J. Virol. 65, 4645\u20134653.","DOI":"10.1128\/jvi.65.9.4645-4653.1991"},{"key":"10.1016\/j.bcp.2021.114462_b0150","doi-asserted-by":"crossref","unstructured":"Adachi, A., Gendelman, H.E., Koenig, S., Folks, T., Willey, R., Rabson, A., and Martin, M.A. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59, 284\u2013291.","DOI":"10.1128\/jvi.59.2.284-291.1986"},{"issue":"6186","key":"10.1016\/j.bcp.2021.114462_b0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/335181a0","article-title":"Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes","volume":"335","author":"Malim","year":"1988","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.bcp.2021.114462_b0160","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1128\/JVI.01107-16","article-title":"Novel acylguanidine-based inhibitor of HIV-1","volume":"90","author":"Mwimanzi","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2021.114462_b0165","doi-asserted-by":"crossref","unstructured":"Tietjen, I., Ntie-Kang, F., Mwimanzi, P., Ongu\u00e9n\u00e9, P.A., Scull, M.A., Idowu, T.O., Ogundaini, A.O., Meva'a, L.M., Abegaz, B.M., Rice, C.M., Andrae-Marobela, K., Brockman, M.A., Brumme, Z.L., and Fedida, D. (2015) Screening of the pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors. PLoS One. 10, e0121099.","DOI":"10.1371\/journal.pone.0121099"},{"key":"10.1016\/j.bcp.2021.114462_b0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/A:1006353008903","article-title":"Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials","volume":"17","author":"Senderowicz","year":"1999","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.bcp.2021.114462_b0175","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cmdc.201700447","article-title":"Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb\/CDK9 inhibitor for the treatment of cancer","volume":"12","author":"L\u00fccking","year":"2017","journal-title":"ChemMedChem."},{"key":"10.1016\/j.bcp.2021.114462_b0180","doi-asserted-by":"crossref","unstructured":"Biglione, S., Byers, S.A., Price, J.P., Nguyen, V.T., Bensaude, O., Price, D.H., and Maury, W. (2007) Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology. 4, 47.","DOI":"10.1186\/1742-4690-4-47"},{"key":"10.1016\/j.bcp.2021.114462_b0185","doi-asserted-by":"crossref","unstructured":"Richard, K., Williams, D.E., Dilip de Silva, E., Brockman, M.A., Brumme, Z.L., Andersen, R.J., and Tietjen, I. (2018) Identification of novel HIV-1 latency-reversing agents from a library of marine natural products. Viruses. 10, 348.","DOI":"10.3390\/v10070348"},{"key":"10.1016\/j.bcp.2021.114462_b0190","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1073\/pnas.86.7.2336","article-title":"Tumor necrosis factor \u03b1 and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor \u03baB","volume":"86","author":"Osborn","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2021.114462_b0195","doi-asserted-by":"crossref","unstructured":"Williams, S.A., Chen, L.F., Kwon, H., Fenard, D., Bisgrove, D., Verdin, E., and Greene, W.C. (2004) Prostratin antagonizes HIV latency by activating NF-\u03baB. J. Biol. Chem. 279, 42008\u201342017.","DOI":"10.1074\/jbc.M402124200"},{"issue":"4","key":"10.1016\/j.bcp.2021.114462_b0200","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.celrep.2012.09.008","article-title":"Reactivation of latent HIV-1 by inhibition of BRD4","volume":"2","author":"Zhu","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2021.114462_b0205","doi-asserted-by":"crossref","unstructured":"Contreras, X., Barboric, M., Lenasi, T., and Peterlin, B.M. (2007) HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K\/Akt and activates HIV transcription. PLoS Pathog. 3, 1459\u20131469.","DOI":"10.1371\/journal.ppat.0030146"},{"issue":"11","key":"10.1016\/j.bcp.2021.114462_b0210","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s11033-015-3881-y","article-title":"Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review","volume":"42","author":"Singh","year":"2015","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/j.bcp.2021.114462_b0215","doi-asserted-by":"crossref","first-page":"1600744","DOI":"10.1002\/mnfr.201600744","article-title":"Targeting the epigenome: screening bioactive compounds that regulate histone deacetylase activity","volume":"61","author":"Godoy","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.bcp.2021.114462_b0220","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3389\/fphar.2020.00905","article-title":"Novel histone deacetylase inhibitors and HIV-1 latency-reversing agents identified by large-scale virtual screening","volume":"11","author":"Divsalar","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114462_b0225","first-page":"12","article-title":"Roles of flavonoids in plants","volume":"6","author":"Samanta","year":"2011","journal-title":"Int. J. Pharm. Sci. Tech."},{"key":"10.1016\/j.bcp.2021.114462_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0973-7847.79093","article-title":"Flavonoids: a versatile source of anticancer drugs","volume":"5","author":"Chahar","year":"2011","journal-title":"Pharmacogn. Rev."},{"key":"10.1016\/j.bcp.2021.114462_b0235","first-page":"12","article-title":"Bioactive flavonoids in medicinal plants: Structure, activity and biological fate","volume":"13","author":"Wang","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2021.114462_b0240","doi-asserted-by":"crossref","unstructured":"Wong, R.W., Balachandran, A., Ostrowski, M.A., and Cochrane, A. (2013) Digoxin suppresses HIV-1 replication by altering viral RNA processing. PLoS Pathog. 9, e1003241.","DOI":"10.1371\/journal.ppat.1003241"},{"key":"10.1016\/j.bcp.2021.114462_b0245","doi-asserted-by":"crossref","unstructured":"Li, Z., Guo, J., Wu, Y., and Zhou, Q. (2013) The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing BRD4 inhibition of Tat-transactivation. Nucleic Acids Res. 41, 277-287.","DOI":"10.1093\/nar\/gks976"},{"issue":"3","key":"10.1016\/j.bcp.2021.114462_b0250","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4161\/cc.23309","article-title":"BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism","volume":"12","author":"Boehm","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2021.114462_b0255","doi-asserted-by":"crossref","first-page":"10657","DOI":"10.1038\/s41598-017-10728-w","article-title":"A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter","volume":"7","author":"Wu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2021.114462_b0260","doi-asserted-by":"crossref","first-page":"4270s","DOI":"10.1158\/1078-0432.CCR-040020","article-title":"Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol","volume":"10","author":"Shapiro","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2021.114462_b0265","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1517\/13543784.2016.1169273","article-title":"Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia","volume":"25","author":"Wiernik","year":"2016","journal-title":"Expert Opin. Investig. Drugs."},{"key":"10.1016\/j.bcp.2021.114462_b0270","unstructured":"ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT02345382, Phase I dose escalation of BAY1143572 in subjets with acute leukemia; 2018 June 25 [cited 9 September 2020]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02345382."},{"key":"10.1016\/j.bcp.2021.114462_b0275","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/cbic.200900303","article-title":"Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication","volume":"10","author":"Ali","year":"2009","journal-title":"ChemBioChem."},{"key":"10.1016\/j.bcp.2021.114462_b0280","doi-asserted-by":"crossref","first-page":"14084","DOI":"10.1074\/jbc.RA120.013031","article-title":"The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal","volume":"295","author":"Richard","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114462_b0285","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2019.03.008","article-title":"HIV \u201cshock and kill\u201d therapy: In need of revision","volume":"166","author":"Abner","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2021.114462_b0290","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cell.2015.02.009","article-title":"A hardwired HIV latency program","volume":"160","author":"Razooky","year":"2015","journal-title":"Cell."},{"key":"10.1016\/j.bcp.2021.114462_b0295","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1021\/acssynbio.6b00373","article-title":"Controlling multi-cycle replication of live-attenuated HIV-1 using an unnatural genetic switch","volume":"6","author":"Yuan","year":"2017","journal-title":"ACS Synth. Biol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:23:14Z","timestamp":1757769794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":59,"alternative-id":["S0006295221000587"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114462","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114462"}}